Cargando…

Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline

INTRODUCTION: There are no blood-based biomarkers for cognitive decline in aging, or mild cognitive impairment (MCI) and Alzheimer's disease (AD). Cumulative evidence suggests that apolipoproteins, complement system, and transthyretin are involved in AD pathogenesis by sequestration of amyloid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchida, Kazuhiko, Shan, Liu, Suzuki, Hideaki, Tabuse, Yo, Nishimura, Yoshinori, Hirokawa, Yoshihiro, Mizukami, Katsuyoshi, Akatsu, Hiroyasu, Meno, Kohji, Asada, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Blood-Based Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876892/ https://www.ncbi.nlm.nih.gov/pubmed/27239510 http://dx.doi.org/10.1016/j.dadm.2015.04.003

Ejemplares similares

Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
por: Liu, Shan, et al.
Publicado: (2019)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Blood protein predictors of brain amyloid for enrichment in clinical trials?
por: Ashton, Nicholas J., et al.
Publicado: (2015)

Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease
por: Sato, Yoshiaki, et al.
Publicado: (2015)

The global Alzheimer's Association round robin study on plasma amyloid β methods
por: Pannee, Josef, et al.
Publicado: (2021)

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker
por: Oh, Esther S., et al.
Publicado: (2015)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia
por: Shen, Xue‐Ning, et al.
Publicado: (2020)

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort
por: Gonzales, Mitzi M., et al.
Publicado: (2022)

Plasma BDNF levels associate with Pittsburgh Compound B binding in the brain
por: Hwang, Kristy S., et al.
Publicado: (2015)

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment
por: Klavins, Kristaps, et al.
Publicado: (2015)

Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology
por: Savica, Rodolfo, et al.
Publicado: (2016)

Molecular markers of neuropsychological functioning and Alzheimer's disease
por: Edwards, Melissa, et al.
Publicado: (2015)

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges
por: O'Bryant, Sid E., et al.
Publicado: (2015)

Repeated systemic inflammation was associated with cognitive deficits in older Britons
por: Tampubolon, Gindo
Publicado: (2015)

MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer's disease
por: Guedes, Joana R., et al.
Publicado: (2015)

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers
por: DeMarshall, Cassandra A., et al.
Publicado: (2016)

Thrombopoietin is associated with δ's intercept, and only in Non-Hispanic Whites
por: Royall, Donald R., et al.
Publicado: (2016)

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging
por: Gupta, Veer Bala, et al.
Publicado: (2015)

Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study
por: Li, Danni, et al.
Publicado: (2016)

Plasma clusterin levels and risk of dementia, Alzheimer's disease, and stroke
por: Weinstein, Galit, et al.
Publicado: (2016)

Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile
por: Winston, Charisse N., et al.
Publicado: (2016)

Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS)
por: Li, Danni, et al.
Publicado: (2016)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
por: Keshavan, Ashvini, et al.
Publicado: (2018)

Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease
por: Peloso, Gina M., et al.
Publicado: (2018)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment
por: Yamamoto-Imoto, Hitomi, et al.
Publicado: (2018)

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
por: Gupta, Veer Bala, et al.
Publicado: (2017)

Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia
por: van Wijk, Nick, et al.
Publicado: (2017)

Alterations of membrane protein expression in red blood cells of Alzheimer's disease patients
por: Várady, György, et al.
Publicado: (2015)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

A blood screening test for Alzheimer's disease
por: O'Bryant, Sid E., et al.
Publicado: (2016)

MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer's disease dementia phenotypes
por: Bettcher, Brianne M., et al.
Publicado: (2016)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Blood-based metabolic signatures in Alzheimer's disease
por: de Leeuw, Francisca A., et al.
Publicado: (2017)

Changes of plasma cGP/IGF‐1 molar ratio with age is associated with cognitive status of Parkinson disease
por: Fan, Dawei, et al.
Publicado: (2020)

Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms
por: Fransquet, Peter Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q25mhp2do4uhedtfg0psoamr6m